Salute e Benessere

StickIt Technologies Inc. Reports Full Year 2024 Financial Results and Business…

StickIt is a technology company that invented and manufactures innovative products ("devices") that can contain varying quantities of Catabolites or Vitamins for recreational and medical users. Its operating model is to establish joint ventures/licensees ("partners") in countries around the world that will establish a production facility in which they will add the cannabinoid content to the "sticks" and "straws" produced and supplied by StickIt. The…
PR Newswire
23/04/2025

FIELD MEDICAL ANNOUNCES FIRST-IN-HUMAN DATA FOR FOCAL PFA IN SCAR-RELATED VT AT…

HRS 2025, the premier global meeting for heart rhythm science, is expected to draw more than 9,000 attendees and 2,000 expert faculty. Field Medical joins this record-breaking lineup with eight presentations spanning live case demonstrations, poster sessions, and a flagship satellite symposium—culminating in the late-breaking VCAS trial on Sunday, April 27, where acute results from the first-in-human evaluation of focal PFA for scar-related ventricular tachycardia (VT) will be unveiled. This…
PR Newswire
23/04/2025

Tiziana Life Sciences Announces University of Massachusetts Commences Dosing…

TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that dosing has commenced at the fourth clinical site in its ongoing Phase 2 trial evaluating intranasal foralumab in patients with non-active secondary progressive multiple sclerosis (na-SPMS). The University of Massachusetts (UMass) has now joined Brigham and...
Nasdaq GlobeNewswire
23/04/2025

Adcendo ApS to Present Data on its Clinical Stage ADCs ADCE-T02 and ADCE-D01 at…

ADCE-D01 is a first-in-class ADC targeting uPARAP conjugated to the Topo-1 inhibitor payload P-1021. uPARAP is a novel endocytic ADC target that is overexpressed in tumors of mesenchymal origin, such as sarcomas, while exhibiting restricted expression in normal tissues. ADCE-D01 is composed of a first-in-class uPARAP-targeting antibody conjugated to an optimized, clinically validated linker payload technology, selected for its superior efficacy and tolerability. Preclinically, ADCE-D01 shows…
PR Newswire
23/04/2025

Tsingke Gene Leads a Delivery Revolution with "Calendar Day Delivery"

Five Core Technological Pillars Behind Calendar Day Delivery Five Core Technological Pillars Behind Calendar Day Delivery 1. Fully Self-Controlled Industrial Chain: Complete independence in synthesis materials, equipment, and processes. 2. Reduced Primer Synthesis Mutation Rate: Minimizing rework by improving initial synthesis accuracy. 3. Enhanced Gene Assembly Efficiency: Increased capability for multi-fragment synthesis. 4. Upgraded Detection Technology: Dual assurance with...
PR Newswire
23/04/2025

Orion Group Interim Report January–March 2025

ORION CORPORATIONINTERIM REPORT 1–3/202523 APRIL 2025 at 12:00 EESTOrion Group Interim Report January–March 2025January–March 2025 HighlightsNet sales totalled EUR 354.6 (January–March 2024: 308.5) million Operating profit was EUR 77.9 (56.0) millionBasic earnings per share were EUR 0.44 (0.31)Cash flow from operating activities per share was EUR 0.55 (0.78)Outlook for 2025 remains unchanged: Net sales are estimated to be EUR 1,550 million to EUR 1,650 million...
Nasdaq GlobeNewswire
23/04/2025

Kanazawa University Research: Visualizing the Mechanics of Hormone-Driven Gene…

Key Points Key Points Estrogen receptors play a critical role in controlling gene activity in many tissues. When estrogen binds to ERα, the protein changes shape, forms a dimer (a molecular pair), and attaches to specific regions of DNA called estrogen response elements (EREs). Although the importance of this process has been known for decades, it had never before been observed unfolding at the single-molecule level in real time. To capture this, the researchers used HS-AFM to scan...
PR Newswire
23/04/2025

Boehringer Ingelheim and Tessellate Bio partner to develop first-in-class…

Ingelheim, Germany and Amsterdam, the Netherlands, 23 April 2025– Boehringer Ingelheim and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, have entered into a research collaboration and global license agreement. Jointly the partners will focus on the development of first-in-class, oral precision treatments for people living with cancer.Cancer continues to be one of the leading challenges in medicine and treatment options for...
Nasdaq GlobeNewswire
23/04/2025

Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as…

For media and investors only Joenja® is the first and only medicine specifically for APDS to be reimbursed within the NHSRecommended for adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)Leiden, the Netherlands, April 23, 2025:Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the National Institute for Health and Care Excellence (NICE) has issued...
Nasdaq GlobeNewswire
23/04/2025

A Breakthrough in Brain Surgery Monitoring: Guarding Lives with Raytron's…

Thermal imaging cameras convert subtle temperature variations from cerebral blood circulation into high-resolution thermal maps, enabling surgeons to "see" vascular flow invisible to the naked eye. This non-invasive thermal imaging technology integrates seamlessly into neurosurgical workflow, such as cerebrovascular bypass, offering continuous intraoperative monitoring without interruption. Thermal imaging cameras convert subtle temperature variations from cerebral blood circulation…
PR Newswire
23/04/2025

Antag Therapeutics expands senior team to support clinical progress

Copenhagen, Denmark, 23 April2025– Antag Therapeutics (“Antag” or “the Company”), a biopharmaceutical company pioneering novel treatments for obesity, today announces the appointment of three new hires to support the Company's next phase of growth following the recent initiation of a Phase 1 trial of its GIP receptor antagonist AT-7687. Dr Jens Chr. Norrild joins as Vice President, Head of Chemistry, Manufacturing and Controls (CMC); Dr Ayna Baladi Nejad as Director of Clinical...
Nasdaq GlobeNewswire
23/04/2025

Implantica opens a new RefluxStop™ center in a new region of Spain, addressing…

H. Univ. Marqués de Valdecilla is the flagship hospital of Cantabria, situated in northern Spain. The hospital was founded nearly 100 years ago and today is a leading center for research focused on innovative new therapies like RefluxStop™. H. Univ. Marqués de Valdecilla is the flagship hospital of Cantabria, situated in northern Spain. The hospital was founded nearly 100 years ago and today is a leading center for research focused on innovative new therapies like RefluxStop™. Dra. Castanedo...
PR Newswire
23/04/2025

Sobi presents clinical data at WFH 2025 Comprehensive Care Summit

Key data to be presented at WFH 2025 Comprehensive Care Summit, Dubai, UAEAltuvoct® (efanesoctocog alfa) Key data to be presented at WFH 2025 Comprehensive Care Summit,Dubai, UAE Altuvoct® (efanesoctocog alfa) Time: 08:45 – 09:00 Location: Great Ballroom . Location: Great Ballroom Thursday 24 April / 11:00 – 11:30 Poster Networking Event: Thursday 24 April / 19:00 – 20:00 Thursday 24 April / 11:00 – 11:30 ...
PR Newswire
23/04/2025

VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination…

VERAXA's Novel BiTAC Platform has the Potential to Deliver Multiple Next-Generation Solid Tumor Cancer Therapies, Including Novel Antibody-Drug Conjugate ("ADC") and Bispecific T-cell Engager ("TCE") Candidates, with Strong and Differentiated Clinical ProfilesCompany Pursuing Multiple Strategic Partnerships and Licensing Opportunities in 2025 and 2026Transaction Values VERAXA at a Pre-money Equity Value of $1.3 BillionActively Working with Existing and New VERAXA Investors to…
Nasdaq GlobeNewswire
23/04/2025

Roche receives CE Mark for its Chest Pain Triage algorithm to enhance detection…

Roche, in collaboration with Universitätsklinikum Heidelberg, has developed a Chest Pain Triage algorithm – a CE-marked IVD medical device 1set to transform cardiac careThis novel algorithm offers a standardised assessment, helping emergency room doctors to make confident clinical decisions in ruling in or ruling out heart attacks (acute myocardial infarction)Cardiovascular disease causes a third of worldwide deaths 2, with chest pain being the second highest reason for emergency...
Nasdaq GlobeNewswire
23/04/2025

OBI Pharma Announces Poster Presentations at the AACR 2025 Annual Meeting for…

Poster Presentations featuring the latest advancements on anti-TROP2 ADCs (OBI 992 and OBI 902), AKR1C3 prodrug (OBI-3424), OBI's novel ADC enabling technologies (GlycOBI® and ThiOBI®), and Globo H science ®technologies. OBI-902 demonstrated superior antitumor activity and favorable PK/PD properties compared to benchmark TROP2 ADCs across various animal models. OBI-992, a cysteine-based TROP2 targeting ADC, demonstrated a differentiated resistance profile compared to benchmark ADCs...
Nasdaq GlobeNewswire
23/04/2025

Investment of Approx. USD 4.5 Million in Development of Diagnostics for…

This project will leverage Fluxus' cutting-edge ultrasensitive detection technology to develop and validate a urine-based TB biomarker lipoarabinomannan (LAM) assay on its automated benchtop immunoassay analyzer. Additionally, the project will design and develop critical components for a portable, ultrasensitive point-of-care (PoC) system that integrates the urine LAM test. This advanced technology will enable rapid, accurate, and accessible diagnosis across a broader patient population…
PR Newswire
23/04/2025

XADAGO/EQUFINA Set to Revolutionize Parkinson's Disease Treatment Landscape |…

Newron Pharmaceuticals/Eisai/Meiji Seika Pharma's XADAGO/EQUFINA (safinamide) Overview Newron Pharmaceuticals/Eisai/Meiji Seika Pharma's XADAGO/EQUFINA (safinamide) Overview XADAGO is a monoamine oxidase B (MAO-B) inhibitor used alongside levodopa/carbidopa to help manage "off" episodes in individuals with Parkinson's disease. While its exact mode of action in treating Parkinson's is not fully understood, it is thought to work by inhibiting MAO-B, thereby reducing dopamine breakdown...
PR Newswire
22/04/2025

Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025

Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website athttps://investor.jazzpharma.com/investors/events-presentations...
PR Newswire
22/04/2025

Press release: Sequana Medical announces the Annual and Extraordinary General…

Sequana Medical announces the Annual and Extraordinary General Meetings of Shareholders on 22 May 2025 Publication of Annual Report 2024Ghent, Belgium – 22 April 2025– Sequana Medical NV (Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today invites the holders of securities issued by the Company to attend the Annual and Extraordinary General Meetings…
Nasdaq GlobeNewswire
22/04/2025

EssilorLuxottica: Disclosure of transactions in own shares

Disclosure of transactions in own shares Paris, France (April 22, 2025 - 6:00 pm)– In accordance with the authorization granted by the Annual Shareholders' Meeting on April 30, 2024, EssilorLuxottica declares that from April 15, 2025, to April 17, 2025, inclusive, the following share buybacks were carried out: Name of the issuerIdentity code of the IssuerDay of the transactionIdentity code of the financial instrumentTotal daily volume (in number of shares)...
Nasdaq GlobeNewswire
22/04/2025

Andrew Taylor joins Novonesis' Executive Leadership Team

Andrew Taylor will assume the role as EVP of Food & Beverage Biosolutions at Novonesis.Please read the full announcement in PDF. Attachment 2025_Andrew_Taylor_joins_ExLT
Nasdaq GlobeNewswire
22/04/2025

Digital Health Market Size to Reach $946.04 Billion by 2030 at CAGR 22.2% -…

The advantages of adopting digital health are numerous, such as remote monitoring, improved medication adherence, and enhanced communication between doctors and patients. Digital wearables allow patients to keep track of their vital signs or other critical health data in real time. To illustrate, in April 2025, Apple Inc. revealed plans to upgrade its AirPods with ambient light sensors that have health monitoring capabilities, such as motion detectors, temperature monitors, blood oxygen, and…
PR Newswire
22/04/2025

Humanized Mouse and Rat Model Market worth US$409.8 million in 2030 with 8.2%…

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=131763955 Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=131763955 Browse in-depth TOC on "Humanized Mouse and Rat Model Market" 189 - Tables31 - Figures204 - Pages By Based on type,the humanized mouse and rat model market has been segmented into humanized mouse models and humanized rat models. The humanized mouse models' segment is further divided into...
PR Newswire
22/04/2025
Altri  Comunicati